n-Hexadecyl--d5 Alcohol | 1219799-18-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: n-Hexadecyl--d5 Alcohol
• 英文别名: 2,2,16,16,16-pentadeuteriohexadecan-1-ol
• CAS: 1219799-18-4
• 化学式: C16H34O
• 分子量: 247.47
• InChiKey: BXWNKGSJHAJOGX-GJZIZAJSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  17
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Pyrimidine phosphonic acid esters
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US10160778B2

  公开（公告）日：2018-12-25

  This invention relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Y1a, Y1b, Y2a, Y2b, Y3a, and Y3b are each independently selected from hydrogen and deuterium, Y4a, Y4b, Y5a, Y5b, Y6a, Y6b, Y7a, Y7b, Y8a, Y8b, Y9a, Y9b, Y10a, Y10b, Y11a, Y11b, Y12a, Y12b, Y13a, Y13b, Y14a, Y14b, Y15a, Y15b, Y16a, Y16b, Y17a, Y17b, Y18a, and Y18b are each deuterium, X1a, X1b, X2a, X2b, X3, X4a, X4b, X5, and X6 are each independently selected from hydrogen and deuterium; and R is CD3. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a viral DNA polymerase inhibitor.

  本发明涉及式（I）化合物： 及其药学上可接受的盐，其中 Y1a、Y1b、Y2a、Y2b、Y3a 和 Y3b 各自独立地选自氢和氘，Y4a、Y4b、Y5a、Y5b、Y6a、Y6b、Y7a、Y7b、Y8a、Y8b、Y9a、Y9b、Y10a、Y10b、Y11a、Y11b、Y12a、Y12b、Y13a、Y13b、Y14a、Y14b、Y15a、Y15b、Y16a、Y16b、Y17a、Y17b、Y18a 和 Y18b 各自为氘，X1a、X1b、X2a、X2b、X3、X4a、X4b、X5 和 X6 各自独立地选自氢和氘；和 R 是 CD3。本发明还提供了包含本发明化合物的组合物，以及这种组合物在治疗通过施用病毒DNA聚合酶抑制剂而获益的疾病和病症的方法中的用途。
• PYRIMIDINE PHOSPHONIC ACID ESTERS BEARING AT LEAST ONE DEUTERIUM ATOM
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP3212656A1

  公开（公告）日：2017-09-06
• PYRIMIDINE PHOSPHONIC ACID ESTERS
  申请人：Concert Pharmaceuticals, Inc.

  公开号：US20170334937A1

  公开（公告）日：2017-11-23

  This invention relates to compounds of Formula (A), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a viral DNA polymerase inhibitor.
• [EN] PYRIMIDINE PHOSPHONIC ACID ESTERS BEARING AT LEAST ONE DEUTERIUM ATOM<br/>[FR] ESTERS D'ACIDE PHOSPHONIQUE DE PYRIMIDINE PORTANT AU MOINS UN ATOME DE DEUTÉRIUM
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2016069630A1

  公开（公告）日：2016-05-06

  This invention relates to compounds of Formula (A), and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a viral DNA polymerase inhibitor.